# Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma

Source: https://onco.cc/trials/nct01037478/  
OnCo record `nct01037478` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Resminostat in Hodgkin lymphoma, run by 4SC AG, completed.

## Summary

Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT01037478 by 4SC AG, with 37 participants recorded, started 2009-12 and reaching its primary completion in 2012-01. Interventions recorded: Resminostat (4SC-201). Conditions recorded: Hodgkin's Lymphoma.

Linked to the drug Resminostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01037478
- Phase: 2
- Setting: A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Sponsor: 4SC AG
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT01037478: https://clinicaltrials.gov/study/NCT01037478

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- drugs: [Resminostat](https://onco.cc/drugs/resminostat/)
- companies: [4SC](https://onco.cc/companies/4sc/)

---
JSON: https://onco.cc/api/v1/entities/nct01037478.json